Clinical Trials Browser

Phase 1 × INDUSTRY × canakinumab × Clear all

NCT03742349 2025-05-18

Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).

Phase 1 Terminated

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT03064854 2022-08-15

PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT02900664 2022-03-29

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Phase 1 Completed

BreastGastrointestinalThoracic

Adenocarcinoma of Lung, Adenocarcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Intestinal Neoplasms, Lung Neoplasms, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Ductal, Triple Negative Breast Neoplasms